Publication abstract
Subject class: Biotech, Life Sciences, Business Development, Funding
Biotechnology Business Development & Funding – ABA225.
Huckle D,
Adams Business Associates: Global Library of World, National and Regional in depth Information and Market Analyses.
(276 pages plus 2005 & 2006 addenda). Price: GB £ 1,900 [single site licence], GB £ 2,700 [Multi-site licence)
Target audience: Chief executives, marketing and sales managers, business development managers, investors and analysts.
This is a primary report from a library of Global, National and Regional Analyses.
This report covers the Business Development and Funding within the Life Science and Biotechnology sectors.
The primary objective of the report is to identify globally where the research funds originate, debate the susceptibility of economic forces and
discuss the development of business models using this knowledge to predict future issues for business development.
Commercial development and Funding Requirements are reviewed against the focus of Life Science research, emerging products and companies.
The structure of Biotechnology research is analysed with special reference to Biotechnology Clusters and individual government objectives for
Biotechnology support. Written in February 2004 this report also contains the updated supplements for all key charts and for changes within the market for
2005 and 2006.
This market sector is strongly led by the impact of Drug Discovery and the need to develop Pharmaceutical procedures to enhance the speed of Drug
Development and cost efficiency. Trends and Issues, Market Segmentation by Country or Region, Applications or customers are explained within the
Multi-layered sector of Life Sciences.
These cover for example Pharmaceuticals, Research Reagents, Equipment, Bioinformatics, Services, Diagnostics, Medical Devices, Biotechnology,
Economic and Political aspects plus much more.
All Global Library reports include market and user segment quantification and projections, commercial aspects and regional, company or institute profiles.
The Report is now integrated with the Genomics & Proteomics in Drug Discovery Report (see ABA 210) and the BioInformatics Report (see ABA 215) into the fully reanalysed report for Global Healthcare Funding & Life Science Business, ABA 305 completed in Autumn of 2007.